“Galderma operates as a leading pure-play dermatology giant at the intersection of beauty and healthcare, consistently outgrowing its broader market. Guided by targets of over 10% compound annual revenue growth and meaningful margin expansion, its asset-light business model provides strong capital allocation flexibility.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.